Compare with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN PHARMACEUTICALS vs LAURUS LABS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN PHARMACEUTICALS LAURUS LABS SUVEN PHARMACEUTICALS/
LAURUS LABS
 
P/E (TTM) x 38.4 26.9 142.9% View Chart
P/BV x 10.5 10.5 99.8% View Chart
Dividend Yield % 0.4 0.4 104.4%  

Financials

 SUVEN PHARMACEUTICALS   LAURUS LABS
EQUITY SHARE DATA
    SUVEN PHARMACEUTICALS
Mar-21
LAURUS LABS
Mar-21
SUVEN PHARMACEUTICALS/
LAURUS LABS
5-Yr Chart
Click to enlarge
High Rs525386 136.1%   
Low Rs10364 161.7%   
Sales per share (Unadj.) Rs39.789.7 44.2%  
Earnings per share (Unadj.) Rs12.118.3 66.1%  
Cash flow per share (Unadj.) Rs13.422.2 60.3%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Avg Dividend yield %0.60.9 71.5%  
Book value per share (Unadj.) Rs46.448.3 96.0%  
Shares outstanding (eoy) m254.57536.60 47.4%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x7.92.5 316.1%   
Avg P/E ratio x25.912.3 211.4%  
P/CF ratio (eoy) x23.510.1 231.7%  
Price / Book Value ratio x6.84.7 145.6%  
Dividend payout %16.510.9 151.2%   
Avg Mkt Cap Rs m79,953120,585 66.3%   
No. of employees `000NANA-   
Total wages/salary Rs m7623,970 19.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,09748,135 21.0%  
Other income Rs m142237 60.2%   
Total revenues Rs m10,24048,372 21.2%   
Gross profit Rs m4,43015,507 28.6%  
Depreciation Rs m3162,051 15.4%   
Interest Rs m117682 17.1%   
Profit before tax Rs m4,13913,011 31.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,0533,173 33.2%   
Profit after tax Rs m3,0869,838 31.4%  
Gross profit margin %43.932.2 136.2%  
Effective tax rate %25.424.4 104.3%   
Net profit margin %30.620.4 149.5%  
BALANCE SHEET DATA
Current assets Rs m6,66530,749 21.7%   
Current liabilities Rs m3,21524,572 13.1%   
Net working cap to sales %34.212.8 266.3%  
Current ratio x2.11.3 165.7%  
Inventory Days Days20011 1,842.3%  
Debtors Days Days37010 3,737.0%  
Net fixed assets Rs m9,09726,758 34.0%   
Share capital Rs m2551,073 23.7%   
"Free" reserves Rs m11,55424,853 46.5%   
Net worth Rs m11,80825,926 45.5%   
Long term debt Rs m3564,292 8.3%   
Total assets Rs m15,76257,507 27.4%  
Interest coverage x36.520.1 181.6%   
Debt to equity ratio x00.2 18.2%  
Sales to assets ratio x0.60.8 76.5%   
Return on assets %20.318.3 111.1%  
Return on equity %26.137.9 68.9%  
Return on capital %35.045.3 77.2%  
Exports to sales %00-   
Imports to sales %034.4 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA16,560 0.0%   
Fx inflow Rs m9,90233,250 29.8%   
Fx outflow Rs m1,36916,560 8.3%   
Net fx Rs m8,53316,690 51.1%   
CASH FLOW
From Operations Rs m3,8347,330 52.3%  
From Investments Rs m-3,114-9,410 33.1%  
From Financial Activity Rs m-7662,547 -30.1%  
Net Cashflow Rs m-45468 -9.6%  

Share Holding

Indian Promoters % 60.0 27.3 219.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 13.8 27.6 50.1%  
FIIs % 8.0 22.8 35.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 40.0 72.7 55.0%  
Shareholders   96,532 394,053 24.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN PHARMACEUTICALS With:   LUPIN  JUBILANT PHARMOVA   CORAL LAB.  OMKAR PHARMACHEM  JENBURKT PH.  



Today's Market

Sensex Falls 1,100 Points from Day's High to End Marginally Lower; Metal & Energy Stocks Witness Selling(Closing)

It was indeed a volatile trading session for Indian share markets today. Benchmark indices reversed course in intraday deals as global cues turned bearish.

Related Views on News

LAURUS LABS 2020-21 Annual Report Analysis (Annual Result Update)

Oct 20, 2021 | Updated on Oct 20, 2021

Here's an analysis of the annual report of LAURUS LABS for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of LAURUS LABS . Also includes updates on the valuation of LAURUS LABS .

SUVEN PHARMACEUTICALS 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of SUVEN PHARMACEUTICALS for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SUVEN PHARMACEUTICALS. Also includes updates on the valuation of SUVEN PHARMACEUTICALS.

Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)

Jun 8, 2021

Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

Don't Sell these Stocks if the Market Falls(Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

How to Find Your Next 10-Bagger in this Market(Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN PHARMACEUTICALS SHARE PRICE


Nov 30, 2021 (Close)

TRACK SUVEN PHARMACEUTICALS

  • Track your investment in SUVEN PHARMACEUTICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN PHARMACEUTICALS

SUVEN PHARMACEUTICALS 5-YR ANALYSIS

COMPARE SUVEN PHARMACEUTICALS WITH

MARKET STATS